###begin article-title 0
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 25 27 25 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 83 89 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 93 101 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946; </italic>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 8 10 8 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 213 218 <span type="species:ncbi:9606">human</span>
CD4+CD25+ regulatory T cells play an essential role in maintaining immune homeostasis and preventing autoimmunity. Therefore, defects in Treg development, maintenance or function have been associated with several human autoimmune diseases including Systemic Lupus Erythematosus (SLE), a systemic autoimmune disease characterized by loss of tolerance to nuclear components and significantly more frequent in females.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 99 100 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 106 108 106 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 575 577 575 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 742 744 742 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 870 880 870 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bona fide </italic>
###xml 885 886 885 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 889 890 889 890 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 894 896 894 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1271 1277 1271 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 1281 1289 1281 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946; </italic>
###xml 1357 1363 1354 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3 </italic>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
###xml 821 829 <span type="species:ncbi:9606">patients</span>
To investigate the involvement of Treg in SLE pathogenesis, we determined the frequency of CD4+CD25+CD45RO+ T cells, which encompass the majority of Treg activity, in the PBMC of 148 SLE patients (76 patients were part of 54 families), 166 relatives and 117 controls. SLE patients and their relatives were recruited in several Portuguese hospitals and through the Portuguese Lupus Association. Control individuals were blood donors recruited from several regional blood donor centers. Treg frequency was significantly lower in SLE patients than healthy controls (z = -6.161, P < 0.00001) and intermediate in the relatives' group. Remarkably, this T cell subset was also lower in females, most strikingly in the control population (z = 4.121, P < 0.001). We further ascertained that the decreased frequency of Treg in SLE patients resulted from the specific reduction of bona fide FOXP3+CD4+CD25+ Treg. Treg frequency was negatively correlated with SLE activity index (SLEDAI) and titers of serum anti-dsDNA antibodies. Both Treg frequency and disease activity were modulated by IVIg treatment in a documented SLE case. The segregation of Treg frequency within the SLE families was indicative of a genetic trait. Candidate gene analysis revealed that specific variants of CTLA4 and TGFbeta were associated with the decreased frequency of Treg in PBMC, while FOXP3 gene variants were associated with affection status, but not with Treg frequency.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 196 197 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 201 203 201 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 213 214 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 218 220 218 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 315 321 315 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 325 333 325 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946; </italic>
###xml 373 379 370 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3 </italic>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
SLE patients have impaired Treg production or maintenance, a trait strongly associated with SLE disease activity and autoantibody titers, and possibly resulting from the inability to convert FOXP3+CD25- into FOXP3+CD25+ T cells. Treg frequency is highly heritable within SLE families, with specific variants of the CTLA4 and TGFbeta genes contributing to this trait, while FOXP3 contributes to SLE through mechanisms not involving a modulation of Treg frequency. These findings establish that the genetic components in SLE pathogenesis include genes related to Treg generation or maintenance.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 405 406 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 552 553 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 795 796 795 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1060 1061 1060 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1158 1159 1158 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1136 1142 <span type="species:ncbi:10090">murine</span>
Immunological tolerance is a key feature of the immune system that allows the organism to discriminate self from nonself, providing defense against foreign pathogens while preventing autoimmunity. This ability of the immune system is controlled by mechanisms of central and peripheral tolerance. Central tolerance involves deletion of self-reactive T cells in the thymus at an early stage of development [1]. However, this mechanism alone is not sufficient for preventing autoimmunity, as autoreactive T cells are also detected in healthy individuals [2]. A second mechanism involves the thymic selection of a population of regulatory T cells (Treg), which dominantly prevents both the activation and the effector function of autoreactive T cells that have eluded other mechanisms of tolerance [3]. The depletion or inactivation of Treg leads to the development of a wide range of autoimmune and inflammatory manifestations such as gastritis, oophoritis, orchitis, thyroiditis, inflammatory bowel disease and spontaneous autoimmune diabetes, in animal models [4]. In addition, reduced numbers of this cellular subset have been found in murine models of SLE [5].
###end p 9
###begin p 10
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 395 401 395 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4</italic>
###xml 401 405 401 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 456 457 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 463 469 463 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 542 543 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 613 614 613 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 729 731 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 831 833 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
T cells expressing the high affinity T Cell Receptor (TCR) for antigens expressed on the thymic epithelium [6] are selected in the thymus, originating Treg cells able to suppress both proliferation and cytokine production by effector cells in a cell-contact dependent manner. The mechanisms involved in Treg generation, maintenance or function have not been fully clarified. For instance, while CTLA-4-/- mice develop an early lymphoproliferative disease [7] and CTLA4 gene expression in the thymus appears instrumental for T cell selection [8], some regulatory T cells can be generated in the absence of CTLA-4 [9]. Given its wide ranged immuno-suppressor activity, TGF-beta was first thought to be a mediator of Treg activity [10], but is nowadays known to play a major role in Treg homeostasis by promoting their proliferation [11].
###end p 10
###begin p 11
###xml 149 151 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 194 195 190 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 199 201 195 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 247 249 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 250 252 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 281 283 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 310 312 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 326 327 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 331 333 327 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 425 427 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 456 462 452 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3 </italic>
###xml 596 598 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 766 768 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
In humans, Treg are highly enriched in the cellular subset expressing CD4, the alpha chain of the IL-2 receptor (CD25) and the memory marker CD45RO [12]. Low numbers or functional defects in CD4+CD25+ T cells have been found in patients with SLE [13,14], immune-mediated diabetes [15], and multiple sclerosis [16]. Natural CD4+CD25+ Treg express the transcription factor FOXP3, which controls their development and function [17]. Functional defects in the FOXP3 gene lead to the absence of Treg production and to Immunodysregulation, Polyendocrinopathy and Enteropathy, X-linked Syndrome (IPEX) [18]. The control of immune cell numbers and effector functions in response to lymphopenia, infection and autoimmune reactivity are also under the strict control of Treg [19].
###end p 11
###begin p 12
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 484 485 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 489 490 489 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 496 498 496 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 653 654 653 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 659 661 659 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 868 869 868 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 873 874 873 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 880 882 880 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 948 953 948 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 955 962 955 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;</italic>
###xml 964 969 961 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3</italic>
###xml 971 975 968 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL2 </italic>
###xml 979 984 976 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD25 </italic>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
SLE is a chronic systemic autoimmune disease with unknown etiology, and thought to result from the interplay between genetic and environmental factors [20]. Multiple immune system defects have been described in patients with this condition, including B cell hyperactivity and increased antinuclear autoantibody production, defects in T cell activation and aberrant cytokine production [21,22]. To establish the involvement of Treg in SLE pathogenesis, we compared the frequency of CD4+CD25+CD45RO+ T cells in SLE patients and controls and correlated it with disease activity and antinuclear autoantibody production. We also analyzed the frequency of CD4+FOXP3+ cells in a subset of patients and investigated Treg frequency variation with disease activity, severity and development and remission of symptoms in two SLE cases. Further, we analyzed the segregation of CD4+CD25+CD45RO+ frequency in SLE-affected families and tested the candidate genes CTLA4, TGFbeta, FOXP3, IL2 and CD25 for association with Treg frequency distribution and with SLE.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Population sample
###end title 14
###begin p 15
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1039 1040 1039 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1290 1291 1290 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
###xml 582 589 <span type="species:ncbi:9606">patient</span>
###xml 828 835 <span type="species:ncbi:9606">patient</span>
###xml 866 874 <span type="species:ncbi:9606">Patients</span>
SLE patients and their relatives were recruited in several hospitals throughout Portugal in collaboration with the Portuguese Lupus Association. A total of 148 SLE patients (136 females and 12 males) were enrolled in the present study. 76 of the SLE patients were part of 54 families, from which 166 relatives (98 females and 68 males) were also included in the study. All patients met the revised 1997 American College of Rheumatology criteria for SLE [23], independently of their disease activity at recruitment. The SLE Disease Activity Index (SLEDAI) [24] was assessed for each patient at the time of collection (SLEDAI range: 0-41). Irreversible damage caused by the disease was calculated using the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) damage index. Information on medication from each patient was collected at recruitment. Patients and their relatives completed a 10 question screening questionnaire [25], used here as an indication of autoimmune disease manifestations in each individual (Table 1). Control individuals (N = 117, 58 females and 59 males) were blood donors recruited from several regional blood centers. The population sample characteristics and the numbers used in each of the subsequent analyses are described in Additional file 1. Approval for this study was obtained from the Portuguese Ethics Committee for Life Sciences Research, and collection of all biological samples was performed after written informed consent from all participating individuals.
###end p 15
###begin p 16
###xml 43 51 <span type="species:ncbi:9606">patients</span>
SLE survey questionnaire and percentage of patients and relatives that gave a positive answer to each question.
###end p 16
###begin title 17
Cell surface staining and flow cytometry
###end title 17
###begin p 18
###xml 113 115 104 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 534 535 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 539 541 506 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 271 276 <span type="species:ncbi:9606">human</span>
PBMC were isolated using Vacutainer CPTtrade mark tubes (Becton Dickinson). For the CD4CD25CD45RO staining 1 x 106 cells were fixed in 2% PFA, washed twice in PBS 2% FCS and subsequently incubated for 20 min at 4degreesC with the optimal dilution of each conjugated anti-human mAb (CD4-FITC, CD25-Cy-chrome, CD31-PE and CD45RO-APC, Becton Dickinson). Cells were washed again and fluorescence intensity staining was analyzed using a FACScan flow cytometer (FACScaliburtrade mark and CellQuesttrade mark software, Becton Dickinson). CD4+CD25+ T cells were defined, for all the individuals, as the population of CD4 positive T cells whose CD25 expression exceeded the level of CD25 positivity seen in the CD4 negative T cells. The CD4-FITC, CD25-APC, FOXP3-PE staining was performed according to eBioscience manufacture protocol.
###end p 18
###begin title 19
Anti-dsDNA autoantibody measurement by quantitative ELISA
###end title 19
###begin p 20
###xml 485 486 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1151 1153 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 418 423 <span type="species:ncbi:9606">human</span>
Reacti-Bindtrade mark EIA plates (Pierce) were coated overnight at 4degreesC with 1 mg/mL purified dsDNA (Sigma-Aldrich). The plates were blocked with a solution of 1% gelatin for 5 h at 4degreesC and incubated overnight at 4degreesC with test plasma (in triplicates) at a total protein concentration was 0.5 mg/mL. Plates were then incubated overnight at 4degreesC with 50 muL of alkaline phosphatase-conjugated anti-human IgG (Sigma-Aldrich) and bound IgG was revealed using 1 mg/mL p-nitrophenyl phosphate (Sigma-Aldrich). Absorbance at 405 nm was measured in an ELISA plate reader (BioRad). Quantification of each reactivity was obtained by fitting ODs to a standard curve present in duplicates on each plate, and consisting of 12 serial dilutions of respective positive control sera. In the readout, one unit was defined as the equivalent of the highest concentration used for the respective positive control serum, which was previously chosen to be below the saturation level. Fractions of one unit were consequently defined by the dilution factor of this standard, at which it yielded an OD equivalent to that obtained for a respective sample [26].
###end p 20
###begin title 21
Genotyping
###end title 21
###begin p 22
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 367 375 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946; </italic>
###xml 546 548 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 549 551 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 565 571 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3 </italic>
###xml 756 758 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 765 769 759 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL2 </italic>
###xml 906 908 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 909 911 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 925 930 919 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD25 </italic>
###xml 1140 1142 1134 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1320 1324 1314 1316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Genomic DNA was isolated from PBMC by standard methods. The polymorphic markers tested were selected for their putative role in gene expression or function. Within the CTLA4 gene, we genotyped a functional SNP involving a missense A>G transition at +49 exon 1 (rs231775) and a 3'UTR microsatelite marker proposed to influence mRNA stability and turnover [27]. In the TGFbeta gene, we genotyped a C>T transition in the promoter (rs1800469) and a G>C SNP in exon 1 (rs1800471), both known to be associated with the serum concentration of TGF-beta [28,29]. Within the FOXP3 gene two microsatelite markers were genotyped (one in intron 0, which has been described as having a promoter/enhancer function and other in intron 5) and a -1128 G>A SNP (rs12843496) [30]. The IL2 gene, -384 G<T (rs2069762) and +114 G>T (rs3087209) in the promoter and in exon 1, respectively, were genotyped as previously described [30,31]. Within the CD25 gene, we genotyped a (CA)n repeat 10 kb upstream of the gene (D10S189) and two SNPs, rs2274037 (a A>G transition in exon 4) and rs1570538 (a C>T transition in the 3'UTR region of CD25) as previously described [32]. The D10S189 microsatelite marker was genotyped using the Applied Biosystems fluorescence based automated sequencer. Semi-automated fragment sizing was performed using GENESCAN(R) 3.1.
###end p 22
###begin title 23
mRNA isolation and quantification
###end title 23
###begin p 24
###xml 34 36 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 1087 1089 1036 1038 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1150 1152 1099 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
Total RNA was isolated from 5 x 106 PBMC using the RNeasy Mini Kit (QIAGEN). The first strand cDNA was generated by reverse transcription with oligo dT primer (Invitrogen). The CTLA-4, TGF-beta, FOXP3, IL-2 and CD25 mRNA levels were quantified with the LightCycler (Roche Molecular Biochemicals) in 33 patients and 24 controls, which were representative of the total population sample. 50 ng of first-stranded cDNA were amplified and real-time fluorimetric intensity of SYBR green I was monitored. RT-PCR reactions consisted in an initial denaturation step at 95degreesC for 10 minutes followed by 45 cycles of denaturation at 95degreesC for 15 seconds, 56degreesC for 5 seconds and 72degreesC for 23 seconds. The individual samples were standardized by the amount of HPRT RNA. This RT-PCR reaction consisted on an initial denaturation step at 95degreesC for 10 minutes followed by 45 cycles of denaturation at 95degreesC for 15 seconds, 60degreesC for 5 seconds and 72degreesC for 23 seconds. Additionally, CTLA-4 and CD25 mRNA expression levels were normalized by the proportion of CD4+ cells, given that these molecules are mainly expressed by CD4+ T cells.
###end p 24
###begin title 25
Statistical analysis
###end title 25
###begin p 26
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 733 738 733 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loci </italic>
###xml 1078 1080 1078 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
Nonparametric analysis of variance was performed using the Mann-Whitney U and Kruskal-Wallis tests to compare the distributions of T cell frequencies in patients and controls. Results were considered significant at the 0.05 level. Heritability estimation was performed by the SOLAR software [33]. In this test the likelihood of the sporadic model of no inheritance is compared with the likelihood of a polygenic model of inheritance. The sporadic model constitutes our null hypothesis in which it is assumed that there is not a genetic component underlying the frequencies of Treg cells. The polygenic model constitutes our testing hypothesis, where the quantitative trait is considered to be determined by a large number of genetic loci acting independently and/or additively. The models are then compared to find the hypothesis that is better supported by the data. Hardy-Weinberg equilibrium (HWE) was analyzed by the HWE exact test. Linkage disequilibrium (LD) between two polymorphic markers was quantified as D' using the HAPLOXT program implemented in the GOLD software [34].
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 27 29 27 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Lower frequency of CD4+CD25+ and CD4+CD25+CD45RO+ cells in SLE patients
###end title 28
###begin p 29
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 216 218 216 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 278 280 278 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 292 293 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 299 301 299 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 452 454 452 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 476 477 476 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 481 483 481 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 490 491 490 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 495 496 495 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 502 504 502 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 607 609 607 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z </italic>
###xml 619 621 619 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 635 637 635 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z </italic>
###xml 647 649 647 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 678 679 678 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 683 685 683 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 692 693 692 693 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 697 698 697 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 704 706 704 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 912 913 912 913 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 917 918 917 918 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 924 926 924 926 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 772 780 <span type="species:ncbi:9606">patients</span>
The previous observation that a CD4+CD25+ T cell subpopulation expressing the CD45RO activation marker exhibits 75% higher suppressive activity [35] suggests that the majority of Treg activity is restricted to CD45RO+ cells. We therefore evaluated the frequency of both CD4+CD25+ and CD4+CD25+CD45RO+ T cell populations in total lymphocyte PMBC samples of SLE patients, their relatives and healthy controls and expressed it as a percentage of total CD4+ cells (Figure 1A). CD4+CD25+ and CD4+CD25+CD45RO+ T cell frequencies were significantly decreased in patients compared to controls (Mann-Whitney U test, z = -6.339, P < 0.00001 and z = -6.161, P < 0.00001, respectively). CD4+CD25+ and CD4+CD25+CD45RO+ T cell distribution in relatives was intermediate between that of patients and controls (Figure 1B). As the frequency distributions of either cell population were identical, the results obtained for the CD4+CD25+CD45RO+ cell subset was considered for the remaining of this study.
###end p 29
###begin p 30
###xml 213 214 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 218 220 218 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 227 228 227 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 232 233 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 237 239 237 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 246 0 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Regulatory T cell frequency is lower in PBMC of SLE patients than in controls (A) Lymphocytes gated according to forward and side scatter (FSC/SSC) from PMBC were screened by flow cytometry for the presence of CD4<sup>+</sup>CD25<sup>+ </sup>and CD4<sup>+</sup>CD25<sup>+</sup>CD45<sup>+ </sup>T cells</bold>
###xml 279 280 279 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 291 293 291 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 313 315 313 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 454 455 454 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 459 461 459 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 468 469 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 473 474 473 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 480 482 480 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 682 683 682 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 687 688 687 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 692 694 692 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 717 719 717 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 849 850 849 850 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 854 855 854 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 859 861 859 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 364 371 <span type="species:ncbi:9606">patient</span>
###xml 490 498 <span type="species:ncbi:9606">patients</span>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
###xml 751 759 <span type="species:ncbi:9606">patients</span>
Regulatory T cell frequency is lower in PBMC of SLE patients than in controls (A) Lymphocytes gated according to forward and side scatter (FSC/SSC) from PMBC were screened by flow cytometry for the presence of CD4+CD25+ and CD4+CD25+CD45+ T cells. The FACS panel representing CD4+CD25+CD45RO+ PBMC is gated on CD4+ cells. Representative FACS stainings from an SLE patient and a healthy individual are shown, (B) box plot representing the frequency of CD4+CD25+ and CD4+CD25+CD45RO+ PBMC in patients (n = 76), relatives (n = 156) and controls (n = 193), showing that SLE patients have a significantly lower Treg frequency than healthy individuals and (C) Relative distribution of CD4+CD25+CD45+ T cell frequency in CD4+ T cells between male and female patients, relatives and controls, showing that females have a significantly lower frequency of CD4+CD25+CD45+ T cell frequency than males.
###end p 30
###begin p 31
###xml 247 248 247 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 252 253 252 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 259 261 259 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 368 370 368 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 387 388 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 392 393 392 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 399 401 399 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 631 632 631 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 636 637 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 643 645 643 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 745 747 745 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 777 779 777 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 22 27 <span type="species:ncbi:9606">women</span>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 465 472 <span type="species:ncbi:9606">patient</span>
###xml 695 703 <span type="species:ncbi:9606">patients</span>
SLE affects primarily women and consequently only about 10% of our patients are male, while our control population is balanced in terms of gender. We therefore tested whether this gender bias was not a confounding factor in our interpretation. CD4+CD25+CD45RO+ T cell frequency was significantly lower in healthy females than in males (Mann-Whitney U test: z = 4.121, P < 0.001). The CD4+CD25+CD45RO+ T cell frequency was also lower in females than in males in the patient and relative groups, although the difference did not reach statistical significance (Figure 1C). Separate analysis within each gender group shows that the CD4+CD25+CD45RO+ T cell frequency is always significantly lower in patients (Mann-Whitney U test, Males: z = -2.504, P = 0.012; females: z = -3.864, P < 0.001).
###end p 31
###begin p 32
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 192 194 192 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 318 319 318 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 325 327 325 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 397 399 397 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 433 435 433 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 341 349 <span type="species:ncbi:9606">patients</span>
CD25 is a marker for both Treg and activated cells. To rule out the possibility that this T cell population is mainly constituted by activated cells we measured the frequency of the CD4+CD45RO+ T cells, since CD45RO expression is associated with early activation events. No difference was found in the frequency of CD4+CD45RO+ cells between patients and controls (Mann-Whitney U test: z = -1.724, P = 0.089), indicating that the CD25+ population was largely a regulatory population.
###end p 32
###begin p 33
###xml 117 119 117 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 165 166 165 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 170 172 170 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 197 198 197 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 202 204 202 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 438 439 438 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 443 444 443 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 450 452 450 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 471 473 469 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 500 502 498 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 518 519 516 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 523 525 521 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 594 596 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 739 740 737 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 746 747 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 751 753 749 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 760 762 758 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 778 779 776 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 783 785 781 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 560 568 <span type="species:ncbi:9606">patients</span>
###xml 670 678 <span type="species:ncbi:9606">patients</span>
To exclude a global thymic output defect, we evaluated the percentage of recent thymic emigrants (RTE) inside the CD4+ population using the phenotypic markers CD45RO-CD31+ [36]. As expected, CD45RO-CD31+ cell frequency decreased with age, but there were no differences between patients and controls in absolute frequency or in the kinetics of decay (Figure 2A). Moreover, the frequency of RTE did not correlate with the percentages of CD4+CD25+CD45RO+ cells (rho = 0.10, P = 0.094). However, the CD31+ cells inside CD4+CD25+ cells decreased faster with age in patients than in controls (Figure 2B), suggesting a defect specifically in thymic Treg cell production in SLE patients. No significant difference was found in the frequency of CD4+CD45RO-CD31+ or CD31+ cells inside CD4+CD25+ between males and females (data not shown).
###end p 33
###begin p 34
###xml 109 110 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 114 116 114 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 139 141 139 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 174 0 174 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) Decrease in the frequency of recent thymic emigrants with age, as indicated by the decrease of the CD45RO<sup>-</sup>CD31<sup>+ </sup>population in total CD4<sup>+ </sup>PBMC in SLE patients and controls</bold>
###xml 213 215 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 236 238 236 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 296 297 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 301 303 301 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 326 328 326 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
(A) Decrease in the frequency of recent thymic emigrants with age, as indicated by the decrease of the CD45RO-CD31+ population in total CD4+ PBMC in SLE patients and controls. (B) Decrease in the frequency of CD31+ cells inside CD4+CD25+ cells with age, as indicated by the decrease of the CD45RO-CD31+ population in total CD4+ PBMC in SLE patients and controls The linear regression curve is shown for each group.
###end p 34
###begin title 35
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 50 52 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
SLE patients display higher frequency of CD4+FOXP3+ cells which are mainly CD25-
###end title 35
###begin p 36
###xml 116 118 116 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 207 209 207 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 221 222 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 323 325 323 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 335 336 335 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 341 343 341 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 449 451 449 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z </italic>
###xml 460 462 460 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 502 503 502 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 507 509 507 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 592 594 592 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z </italic>
###xml 604 606 604 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 681 683 681 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 732 733 732 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 737 739 737 739 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 834 835 834 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 839 841 839 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 851 852 851 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 856 858 856 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 384 392 <span type="species:ncbi:9606">patients</span>
###xml 561 569 <span type="species:ncbi:9606">patients</span>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
###xml 752 760 <span type="species:ncbi:9606">patients</span>
Given the major involvement of FOXP3 in the differentiation and function of Treg, we analyzed the frequency of FOXP3+ cells in a subset of 19 patients and 10 healthy individuals. While the frequency of FOXP3+ cells in CD4+PBMC was not significantly different between patients and controls (Figure 3A), the frequency of CD25+ in the CD4+FOXP3+ cell subset was significantly reduced in patients when compared to healthy controls (Mann-Whitney U test, z = 2.457, P = 0.014) (Figure 3B). In contrast, FOXP3-CD25+ activated cells were significantly increased in SLE patients (Mann-Whitney U test, z = -2.377, P = 0.017) (Figure 3C). This diminished expression of CD25 in patients' FOXP3+ cells indicates that the overall reduction in CD4+CD25+ cells in SLE patients likely results specifically from a defect in the ability to convert FOXP3+CD25- into FOXP3+CD25+ cells.
###end p 36
###begin p 37
###xml 34 36 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 69 71 69 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 95 96 95 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 113 115 113 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 139 141 139 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 0 193 0 193 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Relative distribution of (A) FOXP3<sup>+ </sup>cells in total CD4<sup>+ </sup>PBMC (B) CD25<sup>+ </sup>cells in total CD4<sup>+</sup>FOXP3<sup>+</sup>PBMC and (C) CD25<sup>+ </sup>cells in total CD4<sup>+</sup>FOXP3<sup>- </sup>PBMC between patients (n = 19) and controls (n = 10)</bold>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
Relative distribution of (A) FOXP3+ cells in total CD4+ PBMC (B) CD25+ cells in total CD4+FOXP3+PBMC and (C) CD25+ cells in total CD4+FOXP3- PBMC between patients (n = 19) and controls (n = 10).
###end p 37
###begin title 38
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 15 17 15 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
CD4+CD25+CD45RO+ T cell frequency is negatively correlated with SLE-associated phenotypes
###end title 38
###begin p 39
###xml 304 306 302 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 324 326 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 587 588 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 592 593 590 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 599 601 597 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 653 655 649 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 697 699 691 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 716 718 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 795 796 789 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 800 801 794 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 807 809 801 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 880 882 872 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 900 902 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 631 638 <span type="species:ncbi:9606">patient</span>
Autoantibody production against dsDNA is a hallmark of SLE. We therefore analyzed the plasma immunoreactivity profiles against dsDNA from SLE patients, relatives and healthy individuals. Overall, there is a negative correlation between Treg frequency and anti-dsDNA in the total population (rho = -0.19, P = 0.0026) (Figure 4A), reinforcing the notion that perturbations in the system that maintains immunologic unresponsiveness to self-constituents lead to the loss of peripheral tolerance and to SLE. This negative correlation between anti-dsDNA autoantibodies and the frequency of CD4+CD25+CD45RO+ T cells was also found in our patient (rho = -0.37, P = 0.005) and control groups (rho = -0.30, P = 0.022) (Figure 4A). Surprisingly, there is a positive correlation between the frequency of CD4+CD25+CD45RO+ T cells and anti-dsDNA antibodies in the relatives' group (rho = 0.29, P = 0.0004) (Figure 4A). No difference was found between males and females.
###end p 39
###begin p 40
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 149 150 149 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 154 155 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 161 163 161 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 299 300 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 306 308 306 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 320 322 320 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 381 0 381 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) Negative correlation between CD4<sup>+</sup>CD25<sup>+</sup>CD45RO<sup>+ </sup>T cell frequency and anti-DNA antibody titers in our population sample and correlations between CD4<sup>+</sup>CD25<sup>+</sup>CD45RO<sup>+ </sup>T cell frequency and anti-DNA antibody titers in patients relatives and controls (B) Negative correlation between the percentage of CD25<sup>+</sup>CD45RO<sup>+ </sup>in total CD4<sup>+ </sup>PBMC cells and SLE disease activity index (SLEDAI) (n = 54)</bold>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
(A) Negative correlation between CD4+CD25+CD45RO+ T cell frequency and anti-DNA antibody titers in our population sample and correlations between CD4+CD25+CD45RO+ T cell frequency and anti-DNA antibody titers in patients relatives and controls (B) Negative correlation between the percentage of CD25+CD45RO+ in total CD4+ PBMC cells and SLE disease activity index (SLEDAI) (n = 54).
###end p 40
###begin p 41
###xml 7 8 7 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 19 21 19 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 129 131 127 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 148 150 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 229 231 225 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 305 306 301 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 310 311 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 317 319 313 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 414 416 410 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 478 480 474 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 538 540 534 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 643 644 639 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 648 649 644 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 655 657 651 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 678 680 672 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 809 811 801 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
The CD4+CD25+CD45RO+ T cell frequency was inversely correlated with disease activity measured by the SLEDAI index (rho = -0.502, P = 0.002) (Figure 4B). However, no correlation was found with the SLICC damage index (rho = 0.071, P = 0.658). There was no significant difference between the frequency of CD4+CD25+CD45RO+ T cells in patients untreated or treated with corticosteroids (Kruskall-Wallis Test: z = 0.07, P = 0.94), antimalarial agents (Kruskall-Wallis Test: z = 1.41, P = 0.158), or both drugs (Kruskall-Wallis Test: z = -1.32, P = 0.132). Noteworthy, no correlation was found between total lymphocyte counts and the frequency of CD4+CD25+CD45RO+ T cell (rho = 0.021, P = 0.758), excluding the possibility that lymphopenia led to this phenotype. There was also no correlation with age (rho = 0.153, P = 0.100).
###end p 41
###begin title 42
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 28 30 28 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Variation of CD4+CD25+CD45RO+ T cell frequency with the development and remission of SLE-related symptoms
###end title 42
###begin p 43
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 306 307 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 311 312 311 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 318 320 318 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 644 646 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 682 683 682 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 687 688 687 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 694 696 694 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1158 1159 1158 1159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1163 1164 1163 1164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1170 1172 1170 1172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1207 1209 1207 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 1281 1282 1281 1282 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1286 1287 1286 1287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1293 1295 1293 1295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1330 1332 1330 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 1496 1497 1496 1497 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1501 1502 1501 1502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1508 1510 1508 1510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1554 1556 1554 1556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5E</xref>
###xml 1758 1760 1758 1760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 174 179 <span type="species:ncbi:9606">woman</span>
###xml 249 256 <span type="species:ncbi:9606">patient</span>
###xml 388 393 <span type="species:ncbi:9606">woman</span>
###xml 781 788 <span type="species:ncbi:9606">patient</span>
###xml 1483 1490 <span type="species:ncbi:9606">patient</span>
In two SLE patients variations in CD4+CD25+CD45RO+ T cell frequency as a function of disease onset and progression and with treatment were evaluated. A 33-year-old Caucasian woman was initially enrolled in this study as a healthy relative of an SLE patient. At the time of recruitment, the frequency of CD4+CD25+CD45RO+ T cells in this subject was 4.60% (Figure 5A). One year later, this woman presented classical SLE clinical symptoms, lymphopenia, positive anti-dsDNA antibody, positive lupic anticoagulant and a SLEDAI of 10. Upon establishment of the diagnosis of SLE, a new measurement of Treg frequency showed a decrease to 2.88% (Figure 5B), suggesting the involvement of CD4+CD25+CD45RO+ T cell frequency in the onset of symptoms. In a second case a 67-year-old female SLE patient, diagnosed three years before, developed an SLE flare with symptoms of acute isquemic stroke, hemolytic anemia, impaired renal function, antinuclear, anti-dsDNA and anticardiolipin antibodies and hipocomplementemia. The SLEDAI score was 42. A regimen of low-dose corticosteroids and antimalarials had previously provided a good control of disease. At this point the CD4+CD25+CD45RO+ T cell frequency was 4.22% (Figure 5C). After anticoagulant and intravenous corticosteroid therapies, the CD4+CD25+CD45RO+ T cell frequency was 4.30% (Figure 5D). In addition to anticoagulants and intravenous corticosteroids therapies, IVIg therapy administration was deemed necessary. Upon IVIg treatment, the patient's CD4+CD25+CD45RO+ T cell frequency increased to 7.12% (Figure 5E) and she showed progressive clinical and laboratorial improvement, and the SLEDAI score decreased to 12 after three weeks of treatment. Taken together these results support the idea that decreased CD25+ T cell frequency is associated with disease activity.
###end p 43
###begin p 44
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 15 17 15 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CD4<sup>+</sup>CD25<sup>+</sup>CD45RO<sup>+ </sup>T cell frequency of an SLE patient before (A) and after (B) SLE diagnosis</bold>
###xml 386 387 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 391 392 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 398 400 398 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 440 441 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 445 446 445 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 452 454 452 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 469 471 469 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 44 51 <span type="species:ncbi:9606">patient</span>
###xml 140 147 <span type="species:ncbi:9606">patient</span>
CD4+CD25+CD45RO+ T cell frequency of an SLE patient before (A) and after (B) SLE diagnosis. (C) CD4+CD25+CD45RO+ T cell frequency of an SLE patient at the time of flare, (D) upon corticosteroid and anticoagulant therapy and (E) after IVIg administration. Lymphocytes gated according to forward and side scatter (FSC/SSC) from PBMC were screened by flow cytometry for the presence of CD4+CD25+CD45RO+ T cells. The FACS panel representing CD4+CD25+CD45RO+ is gated on CD4+ cells.
###end p 44
###begin title 45
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 26 28 26 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Peripheral CD4+CD25+CD45RO+ T cell frequency is highly heritable
###end title 45
###begin p 46
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 57 58 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 64 66 64 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Relatives of SLE patients presented intermediate CD4+CD25+CD45RO+ T cell frequencies between patients and controls (Figure 1B), suggesting that Treg frequency might represent a genetic trait. Any potential bias due to recruitment design was excluded based on the following observations: for each family all samples were collected and processed on the same day; there were no significant differences in Treg frequency between families collected in different days. Treg frequencies in genetically unrelated family members and in controls collected and processed on the same day are within the range of healthy controls analyzed during the whole period of the study.
###end p 46
###begin p 47
###xml 10 11 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 22 24 22 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 173 175 171 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 204 205 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 281 282 279 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 286 287 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 293 295 291 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 510 511 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 515 516 513 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 522 524 520 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 684 685 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 769 770 767 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 774 775 772 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 781 783 779 781 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 824 826 822 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 843 844 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 939 940 937 938 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 944 945 942 943 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 951 953 949 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1009 1010 1007 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1014 1015 1012 1013 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1021 1023 1019 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 654 662 <span type="species:ncbi:9606">patients</span>
A high CD4+CD25+CD45RO+ T cell frequency heritability, defined as the proportion of variation of this trait attributable to genetic factors, was estimated at 0.85 +/- 0.09 (P = 1.05e-10) (Additional file 2). As for most complex traits, there was no clear segregation pattern of CD4+CD25+CD45RO+ T cell frequency with affection status in the families. However, because relatives often present SLE-related autoimmunity symptoms even when not meeting the full diagnostic criteria, we tested the association of CD4+CD25+CD45RO+ T cell frequency with the severity of these suboptimal autoimmune symptoms through a 10-item survey questionnaire administered to patients and relatives (Table 1). The number of positive answers was inversely correlated with the frequency of CD4+CD25+CD45RO+ T cells (Kruskall-Wallis test: H = 20.7, P = 0.014) (Figure 6), as expected if the extent of clinical manifestations is associated with the frequency of CD4+CD25+CD45RO+ T cells. The results therefore provide evidence that CD4+CD25+CD45RO+ T cells frequency constitutes a genetic trait associated with SLE manifestations, which can be used for genetic mapping.
###end p 47
###begin p 48
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 233 234 233 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 240 242 240 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 312 0 312 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Relative distribution of CD4<sup>+</sup>CD25<sup>+</sup>CD45RO<sup>+ </sup>T cell frequency in patients and their relatives (n = 231) with the number of positive answers to the survey questionnaire, indicating a negative correlation between the frequency of CD4<sup>+</sup>CD25<sup>+</sup>CD45RO<sup>+ </sup>T cells and the number of positive answers to the survey questionnaire</bold>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Relative distribution of CD4+CD25+CD45RO+ T cell frequency in patients and their relatives (n = 231) with the number of positive answers to the survey questionnaire, indicating a negative correlation between the frequency of CD4+CD25+CD45RO+ T cells and the number of positive answers to the survey questionnaire.
###end p 48
###begin title 49
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 34 36 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 82 90 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946; </italic>
Lower frequency of CD4+CD25+CD45RO+ T cells is associated with specific CTLA4 and TGFbeta gene variants
###end title 49
###begin p 50
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 123 130 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;</italic>
###xml 132 137 129 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3</italic>
###xml 139 143 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL2 </italic>
###xml 147 152 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD25 </italic>
###xml 176 177 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 181 182 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 188 190 185 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 346 352 343 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 388 389 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 393 394 390 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 400 402 397 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 462 464 459 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 574 575 571 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 579 580 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 586 588 583 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 617 618 614 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 803 805 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 812 820 809 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946; </italic>
###xml 892 893 886 887 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 897 898 891 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 904 906 898 900 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 947 949 941 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1017 1018 1011 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1022 1023 1016 1017 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1029 1031 1023 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1046 1047 1040 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
The evidence for familiar transmission prompted us to test putative functional polymorphisms in the candidate genes CTLA4, TGFbeta, FOXP3, IL2 and CD25 for association with CD4+CD25+CD45RO+ T cell frequency. All genotypic distributions were in HWE and all the polymorphic markers within the same gene were in LD. A significant association of the CTLA4 3'UTR microssatelite marker with CD4+CD25+CD45RO+ T cell frequency was found (Kruskal-Wallis test: H = 40.57, P = 0.009), with genotypes 104/104 and 106/106 associated with lower (2.64%) and higher (5.47%) frequency of CD4+CD25+CD45RO+ T cells, respectively (Table 2). This result is particularly relevant because, in our sample, allele 104 has previously been found to increase susceptibility to disease, while allele 106 showed a protective effect [27]. The TGFbeta rs180047 SNP was also significantly associated with the frequency of CD4+CD25+CD45RO+ T cells (Kruskal-Wallis test: H = 8.099, P = 0.004). Heterozygosis was associated with lower frequencies of CD4+CD25+CD45RO+ T cells (Table 2). Because the C allele has very low frequency in the general population (6%), there were no homozygous individuals for this allele in our sample.
###end p 50
###begin p 51
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 68 81 68 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946; FOXP3</italic>
###xml 83 87 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL2 </italic>
###xml 91 96 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD25 </italic>
Distribution of Treg frequency according to genotypes of the CTLA4, TGFbeta FOXP3, IL2 and CD25 genes (non-parametric analysis of variance - Kruskall-Wallis test).
###end p 51
###begin p 52
N represents the number of individuals.
###end p 52
###begin p 53
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3 </italic>
###xml 147 149 145 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 157 159 155 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 174 176 170 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 185 187 181 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 217 218 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 396 398 390 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 406 408 400 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P=</italic>
###xml 470 472 462 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 480 482 472 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 497 498 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 534 535 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 539 540 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 546 548 538 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 572 573 564 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 654 655 646 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 659 660 651 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 666 668 658 660 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
Both the FOXP3 rs12843496 SNP and the intron 0 marker, located in the promoter/enhancer region of the gene, were nominally associated with SLE (chi2 = 6.14, P = 0.013 and chi2 = 10.30, P = 0.036, respectively) (Table 3). The A allele of rs12843496 was more frequent in patients than in controls. The susceptibility allele 4 of the intron 0 microsatellite marker was more frequent in patients (chi2 = 6.63, P=0.01) and a protective allele 6 more frequent in controls (chi2 = 4.03, P = 0.04) (Table 3). No association was found with CD4+CD25+CD45RO+ T cell frequency (Table 2). There was no evidence for association of any other tested gene marker with CD4+CD25+CD45RO+ T cell frequency or with SLE (data not shown).
###end p 53
###begin p 54
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3 </italic>
Genetic association between FOXP3 markers and SLE.
###end p 54
###begin p 55
###xml 36 38 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 66 72 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3 </italic>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
Allele and genotype frequencies, chi2 test and Odds Ratio for the FOXP3 rs12843496, intron 0 and intron 5 microssatelites in SLE patients and healthy individuals.
###end p 55
###begin p 56
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 53 61 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946; </italic>
###xml 113 114 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 118 119 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 125 127 122 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 213 219 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3 </italic>
###xml 269 270 266 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 274 275 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 281 283 278 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Taken together these results indicate that CTLA4 and TGFbeta gene variants contribute to the determination of CD4+CD25+CD45RO+ T cell frequency in PBMC, independently of disease activity, while the involvement of FOXP3 gene variants in SLE is likely not mediated by CD4+CD25+CD45RO+ T cell frequency.
###end p 56
###begin p 57
###xml 106 107 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 111 112 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 118 120 115 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 311 313 308 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 367 373 364 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3 </italic>
###xml 416 418 413 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 473 474 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 478 479 475 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 485 487 482 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
No correlation was found between CTLA-4, TGF-beta, IL-2 or CD25 expression levels and the frequency of CD4+CD25+CD45RO+ T cells, disease status or marker genotypes (data not shown). There was a trend towards higher levels of FOXP3 mRNA in SLE patients, although not significant (Mann-Whitney U-test: z = -1.78, P = 0.075), and in individuals carrying the A allele of FOXP3 rs12843496 (Mann-Whitney U-test: z = 4.95, P = 0.026). These results suggest that variability in CD4+CD25+CD45RO+ T cell frequency associated with SLE is not influenced by altered expression of any of the tested genes.
###end p 57
###begin title 58
Discussion
###end title 58
###begin p 59
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 89 91 89 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 274 275 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 281 283 281 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 361 362 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 366 368 366 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 378 379 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 383 384 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 394 395 394 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 399 400 399 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 406 408 406 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 688 689 688 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 693 694 693 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 700 702 700 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 925 931 925 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 935 943 935 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946; </italic>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
###xml 522 529 <span type="species:ncbi:9606">patient</span>
###xml 848 856 <span type="species:ncbi:9606">patients</span>
The present study supports and expands previous observations of decreased CD4+CD25+CD45RO+ T cell frequency in SLE patients. It further demonstrates a clear gender difference in the distribution of this regulatory T cell subset and provides evidence suggesting that CD4+CD25+CD45RO+ T cell frequency variation may result from a defect in the conversion of FOXP3+CD25- into FOXP3+CD25+cells. CD4+CD25+CD45RO+ T cell frequency is shown to be negatively correlated with disease activity and with anti-dsDNA antibodies in the patient and control groups, and to change with development and remission of SLE symptoms in two documented cases. The study also established that the frequency of CD4+CD25+CD45RO+ T cells is highly heritable in families affected with SLE, that it is negatively correlated with the severity of SLE-associated manifestations in patients and relatives, and that it is influenced by genetic variants in the CTLA4 and TGFbeta genes.
###end p 59
###begin p 60
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 168 169 168 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 173 174 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 180 182 180 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 470 472 470 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 855 857 855 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 880 882 880 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 888 890 888 890 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 902 904 902 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 949 950 949 950 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 954 955 954 955 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 961 963 961 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1056 1066 1056 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bona fide </italic>
###xml 1098 1099 1098 1099 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1104 1106 1104 1106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1218 1220 1218 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1224 1226 1224 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1281 1283 1281 1283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1287 1289 1287 1289 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1299 1301 1299 1301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1305 1307 1305 1307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1449 1451 1449 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1461 1462 1461 1462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1467 1469 1467 1469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1489 1493 1489 1493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1567 1569 1567 1569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 159 164 <span type="species:ncbi:9606">human</span>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
###xml 617 625 <span type="species:ncbi:9606">patients</span>
###xml 723 731 <span type="species:ncbi:9606">patients</span>
###xml 799 807 <span type="species:ncbi:9606">patients</span>
###xml 1141 1149 <span type="species:ncbi:9606">patients</span>
###xml 1164 1172 <span type="species:ncbi:9606">patients</span>
###xml 1365 1373 <span type="species:ncbi:9606">patients</span>
###xml 1493 1497 <span type="species:ncbi:10090">mice</span>
###xml 1561 1565 <span type="species:ncbi:10090">mice</span>
We initially analyzed the frequency of Treg with the available anti-CD25 an CD45RO antibodies as described by Jonuleit et al. [35], who have demonstrated that human CD4+CD25+CD45RO+ T cells are highly enriched in T cells with suppressor properties. CD25 and CD45RO are also markers of activation and one could argue that our measurement concerned conventional activated cells. Several observations indicate that this is not the case. First, the total frequency of CD45RO+ cells was not significantly different between patients' and controls' PBMC, indicating that conventional activated cells are not enriched in SLE patients' PMBC. Second, once a FOXP3 antibody became available, we have tested this marker in a subset of patients. All together our analyses reveal that, when compared to controls, patients had a significantly decreased frequency of CD25+ cells of either the CD4+ CD45RO+ or the FOXP3+ phenotype, supporting the notion that the CD4+CD25+CD45RO+ T cell subset is enriched in Treg. Hence, the analyses we presented here most likely concern bona fide Treg. Furthermore, while the CD4+FOXP3+ cell subset was comparable between patients and controls, patients had a significantly higher frequency of FOXP3+ CD25- cells, suggesting that they are unable to convert FOXP3+ CD25- into FOXP3+ CD25+ cells. Previous observations endorse this hypothesis: SLE patients display multiple signaling defects leading to a defective IL-2 production [37], and CD4+FOXP3+ thymocytes from IL-2-/- mice have very few cells expressing CD25 when compared to wild type mice [38]. In fact, IL-2 does not seem to be required for the induction of FOXP3 expression but is required for the survival and expansion of Treg cells in the periphery, leading to autoimmune manifestations.
###end p 60
###begin p 61
###xml 24 25 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 29 31 29 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 78 79 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 90 92 90 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 179 180 179 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 184 186 184 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 190 192 190 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 411 412 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 416 417 416 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 423 425 423 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 625 626 625 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 630 631 630 631 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 637 639 637 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
The percentage of CD45RO-CD31+ RTE was not correlated with disease or with CD4+CD25+CD45RO+ T cell frequency, ruling out a defect in thymic export. The faster decrease rate of CD4+CD25+ CD31+ cells in SLE patients, however, is indicative of a specific thymic defect leading to a decreased Treg production and thus contributing to the lower frequency of these cells in the periphery. The observed decrease of CD4+CD25+CD45RO+ T cell frequency in patients might also result from cell migration to the sites of inflammation. However, this hypothesis seems unlikely because patients with rheumatoid arthritis display enriched CD4+CD25+CD45RO+ T cells not only in inflamed joints but also in peripheral blood [39].
###end p 61
###begin p 62
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 39 41 39 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 339 346 <span type="species:ncbi:9606">patient</span>
The difference found in CD4+CD25+CD45RO+ T cell frequency between males and females is remarkable, given the much higher prevalence of SLE in females. This difference is very significant in the control population, suggesting this may be a gender specific trait that renders females more susceptible to SLE. The lack of significance in the patient group may be due to the very small number of males, while in the relatives' group this might be explained by the high heterogeneity of this population, where only some individuals carry the disease susceptibility factors.
###end p 62
###begin p 63
###xml 43 44 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 55 57 55 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 462 463 462 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 467 468 467 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 474 476 474 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
The significant negative correlation of CD4+CD25+CD45RO+ T cell frequency with anti-dsDNA antibodies observed in the patients and in the relatives suggests that these cells may be able to inhibit antinuclear antibody production by B cells, and therefore an additional mechanism through which loss of immunological tolerance may be achieved in SLE. This phenomenon may also occur in the relatives, but the fact that they display a positive correlation between CD4+CD25+CD45RO+ T cell frequency and anti-dsDNA antibodies may represent a compensation effect in which the relatives' are able to overcome this pathogenic mechanism.
###end p 63
###begin p 64
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 15 17 15 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 331 332 331 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 336 337 336 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 343 345 343 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 669 670 669 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 674 675 674 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 681 683 681 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
CD4+CD25+CD45RO+ T cell frequency was also associated with disease activity and with the extent of clinical manifestations. This suggests a direct involvement in disease development and prognosis, which is corroborated by the variation observed with onset and remission of symptoms in the two documented cases. The frequency of CD4+CD25+CD45RO+ T cells was not associated with the use of immunosuppressive drugs. Whether these therapies affect basal frequencies of Treg was not addressed in the present work as it would require longitudinal studies. Interestingly, in one case the clinical improvement that followed IVIg administration was associated with increased CD4+CD25+CD45RO+ T cell frequency, suggesting that this treatment may influence Treg generation or maintenance [40].
###end p 64
###begin p 65
###xml 7 8 7 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 19 21 19 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 457 458 457 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 462 463 462 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 469 471 469 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 597 598 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 602 603 602 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 609 611 609 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
The CD4+CD25+CD45RO+ T cell frequency was highly heritable in the affected families and was also strongly correlated with the extent of autoimmune manifestations in patients and in affected and unaffected relatives, in concordance with the clustering of autoimmune diseases and/or autoimmune-related phenotypes observed in these families. These findings are of particular importance because they show a contribution of genetic factors to the decrease in CD4+CD25+CD45RO+ T cell frequency and thus substantiate a genetic basis for SLE. Although we still cannot establish whether the decrease in CD4+CD25+CD45RO+ T cells is a cause or a consequence of autoimmune manifestations in SLE, we show evidence for the existence of genetic factors that, by influencing this trait, may contribute to SLE.
###end p 65
###begin p 66
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 32 34 32 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 271 277 271 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 281 289 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946; </italic>
###xml 342 343 339 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 347 348 344 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 354 356 351 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 664 665 658 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 669 670 663 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 676 678 670 672 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 702 710 <span type="species:ncbi:9606">patients</span>
The frequency of CD4+CD25+CD45RO+ T cells likely results from a combination of processes regulating their expansion and survival in the periphery, and therefore multiple genetic factors may contribute to this trait. This study provided evidence for an involvement of the CTLA4 and TGFbeta genes. The specific polymorphisms associated with CD4+CD25+CD45RO+ cell frequency were not correlated with CTLA-4 and TGF-beta mRNA expression level variation; expression levels in turn were not associated with cell variation or with disease status, indicating that a functional defect in these genes, rather than changes in expression levels, contributes to the observed CD4+CD25+CD45RO+ T cell phenotype in SLE patients.
###end p 66
###begin p 67
###xml 105 107 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 108 110 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 119 123 116 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 158 159 155 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 163 165 160 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 308 310 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 354 355 345 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 359 361 350 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 380 388 371 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 477 479 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 551 552 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 556 558 547 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 578 580 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 3 8 <span type="species:ncbi:10090">mouse</span>
###xml 419 425 <span type="species:ncbi:10090">murine</span>
###xml 485 491 <span type="species:ncbi:9606">humans</span>
###xml 692 698 <span type="species:ncbi:9606">humans</span>
In mouse models the generation and expansion of Treg are dependent on CTLA-4 and TGF-beta respectively, [41-46]. CTLA-4-/- animals have reduced numbers of CD4+CD25+ T cells with reduced regulatory capacity, while TGF-beta regulates the Treg cell pool size and expression of the Treg commitment factor Foxp3 [11]. TGFbeta has also been shown to induce CD4+CD25+ regulatory T cells in vitro, which were able to prevent a murine lupus-like syndrome and graft versus host disease [47]. In humans, it was demonstrated that it has the capacity to expand CD4+CD25+ in normal subjects [48]. Our results therefore extend the role of these genes in the regulation of Treg frequency and autoimmunity to humans.
###end p 67
###begin p 68
###xml 114 120 114 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3 </italic>
###xml 146 150 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL2 </italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD25 </italic>
###xml 304 310 304 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOXP3 </italic>
###xml 372 373 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 377 378 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 384 386 384 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 830 831 830 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 836 838 836 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 724 732 <span type="species:ncbi:9606">patients</span>
###xml 856 864 <span type="species:ncbi:9606">patients</span>
Other Treg specific candidate genes that may contribute to the determination of the size of the Treg pool are the FOXP3 commitment factor and the IL2 and CD25 genes, which deliver crucial growth and/or survival signals to these cells. In the study population, a promoter polymorphism (rs12843496) in the FOXP3 gene was associated with SLE but not with the frequency of CD4+CD25+CD45RO+ T cells, indicating that susceptibility to the disease is mediated by mechanisms other than influencing Treg frequency. The rs12843496 allele A associated with SLE creates a putative binding site to the transcriptional activator PLAG1 in the FOXP3 promoter region, which may explain the slightly higher FOXP3 mRNA expression found in SLE patients. A compensatory mechanism can be hypothesized to account for the maintenance of a normal mean CD4+FOXP3+ cell frequency in patients even in the presence of increased frequency of this allele, and is plausible since FOXP3 can be upregulated by other cytokines.
###end p 68
###begin p 69
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL2 </italic>
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD25 </italic>
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 63 65 63 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The IL2 and CD25 genes were not associated with CD4+CD25+CD45RO+ T cell frequency or with SLE. It should be remarked that the study population sample is small and that we focused on genotyping known functional polymorphisms because of their previously reported relevance, but did not fully cover genetic variation in any of these genes. Our genetic results should therefore be considered preliminary.
###end p 69
###begin title 70
Conclusion
###end title 70
###begin p 71
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 264 265 264 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 276 278 276 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 472 480 <span type="species:ncbi:9606">patients</span>
###xml 556 564 <span type="species:ncbi:9606">patients</span>
In conclusion, we report that low peripheral CD4+CD25+CD45RO+ T cell frequency is a genetically determined predisposing factor for SLE development. Our results demonstrate the contribution of specific genes and suggest pathways involved in the establishment of CD4+CD25+CD45RO+ T cell frequency. Whether a defect in number or function is a prerequisite for SLE development remains to be understood. Most importantly, our findings open new perspectives for therapy for SLE patients based on the manipulation of Treg. Criteria for the selection of candidate patients for Treg based therapy remains to be fully established but likely should include evaluation of Treg frequency and analysis of genes involved in Treg generation or maintenance, strongly benefiting the management of this autoimmune disease.
###end p 71
###begin title 72
Authors' contributions
###end title 72
###begin p 73
###xml 225 233 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
###xml 673 676 <span type="species:ncbi:12202?0.5">LMV</span>
MB planed and conducted experiments, prepared the database, performed the statistical analyses and wrote the manuscript; RCF and LL conducted experiments; MFF and CC conducted experiments and performed clinical evaluation of patients and their relatives; ES and MA collected samples, performed clinical evaluation of patients and their relatives and prepared the database; BM, RA, and CV selected families for the study and supervised the blood collection; CF participated in the experimental design, selected families for the study, performed clinical evaluation of patients and their relatives and discussed the results; JFV participated in the autoantibody experiments; LMV collected samples and revised the manuscript; JD participated in the experimental design, discussed the results and wrote the manuscript; AV supervised the overall project, participated in the experimental design, discussed the results and wrote the manuscript. All authors read and approved the final manuscript.
###end p 73
###begin title 74
Supplementary Material
###end title 74
###begin title 75
Additional file 1
###end title 75
###begin p 76
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Total sample characteristics and samples used in each of the analyses.</bold>
Total sample characteristics and samples used in each of the analyses.
###end p 76
###begin p 77
Click here for file
###end p 77
###begin title 78
Additional file 2
###end title 78
###begin p 79
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 30 31 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 37 39 37 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Heritability test for CD4<sup>+</sup>CD25<sup>+</sup>CD45RO<sup>+ </sup>regulatory T cell frequency in SLE families.</bold>
Heritability test for CD4+CD25+CD45RO+ regulatory T cell frequency in SLE families.
###end p 79
###begin p 80
Click here for file
###end p 80
###begin title 81
Acknowledgements
###end title 81
###begin p 82
###xml 183 191 <span type="species:ncbi:9606">patients</span>
The authors would like to thank Isabel Reis, Ana Tam, Maria Joao Antunes, the Associacao dos Doentes com Lupus, and also Leonor Miranda, for their precious help in the recruitment of patients and collection of blood samples. We also thank the Servico de Imunohemoterapia, Hospital Egas Moniz, as well as all the blood donors for their participation in this study. The authors thank Sofia Marques for her help in the mRNA experiments, Isabel Marques for her bioinformatics support and Antonio Coutinho for advice and critical reading of the manuscript. M. Barreto was supported by Fundacao para a Ciencia e Tecnologia.
###end p 82
###begin article-title 83
Peripheral selection of the T cell repertoire
###end article-title 83
###begin article-title 84
Homeostasis and self-tolerance in the immune system: turning lymphocytes off
###end article-title 84
###begin article-title 85
Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance
###end article-title 85
###begin article-title 86
Naturally Arising CD4+ Regulatory T Cells for Immunologic Self-Tolerance and Negative Control of Immune Responses
###end article-title 86
###begin article-title 87
###xml 58 64 <span type="species:ncbi:10090">murine</span>
The role of CD4CD25 T cells in autoantibody production in murine lupus
###end article-title 87
###begin article-title 88
Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells
###end article-title 88
###begin article-title 89
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4
###end article-title 89
###begin article-title 90
Role of ctla-4 in the activation of single- and double-positive thymocytes
###end article-title 90
###begin article-title 91
The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells
###end article-title 91
###begin article-title 92
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease
###end article-title 92
###begin article-title 93
TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes
###end article-title 93
###begin article-title 94
###xml 96 101 <span type="species:ncbi:9606">human</span>
Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood
###end article-title 94
###begin article-title 95
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Quantification of regulatory T cells in patients with systemic lupus erythematosus
###end article-title 95
###begin article-title 96
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus
###end article-title 96
###begin article-title 97
Multiple immuno-regulatory defects in type-1 diabetes
###end article-title 97
###begin article-title 98
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis
###end article-title 98
###begin article-title 99
Control of regulatory T cell development by the transcription factor Foxp3
###end article-title 99
###begin article-title 100
Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome
###end article-title 100
###begin article-title 101
Control of immune homeostasis by naturally arising regulatory CD4+ T cells
###end article-title 101
###begin article-title 102
Systemic lupus erythematosus
###end article-title 102
###begin article-title 103
B-cell and T-cell function in systemic lupus erythematosus
###end article-title 103
###begin article-title 104
Cytokines and systemic lupus erythematosus
###end article-title 104
###begin article-title 105
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
###end article-title 105
###begin article-title 106
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE
###end article-title 106
###begin article-title 107
Undiagnosed systemic lupus erythematosus in the community
###end article-title 107
###begin article-title 108
###xml 32 37 <span type="species:ncbi:9606">human</span>
Heritable factors shape natural human IgM reactivity to Ro60/SS-A and may predispose for SLE-asssociated IgG anti-Ro and anti-La autoantibody production
###end article-title 108
###begin article-title 109
Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus
###end article-title 109
###begin article-title 110
Genetic control of the circulating concentration of transforming growth factor type beta1
###end article-title 110
###begin article-title 111
###xml 115 123 <span type="species:ncbi:9606">patients</span>
###xml 137 148 <span type="species:ncbi:11103">hepatitis C</span>
Analysis of the transforming growth factor-beta1 (TGF-beta1) codon 25 gene polymorphism by LightCycler-analysis in patients with chronic hepatitis C infection
###end article-title 111
###begin article-title 112
A functional polymorphism in the promoter/enhancer region of the FOXP3/Scurfin gene associated with type 1 diabetes
###end article-title 112
###begin article-title 113
Lack of association between -384 and 114 IL-2 gene polymorphisms and rheumatoid arthritis
###end article-title 113
###begin article-title 114
IL2RA/CD25 polymorphisms contribute to multiple sclerosis susceptibility
###end article-title 114
###begin article-title 115
Multipoint quantitative-trait linkage analysis in general pedigrees
###end article-title 115
###begin article-title 116
GOLD - graphical overview of linkage disequilibrium
###end article-title 116
###begin article-title 117
###xml 50 55 <span type="species:ncbi:9606">human</span>
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood
###end article-title 117
###begin article-title 118
###xml 93 98 <span type="species:ncbi:9606">human</span>
Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood
###end article-title 118
###begin article-title 119
Altered signal transduction in SLE T cells
###end article-title 119
###begin article-title 120
A function for interleukin 2 in Foxp3-expressing regulatory T cells
###end article-title 120
###begin article-title 121
###xml 69 77 <span type="species:ncbi:9606">patients</span>
CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease
###end article-title 121
###begin article-title 122
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis
###end article-title 122
###begin article-title 123
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation
###end article-title 123
###begin article-title 124
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
###end article-title 124
###begin article-title 125
###xml 14 19 <span type="species:ncbi:9606">human</span>
Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells
###end article-title 125
###begin article-title 126
###xml 71 76 <span type="species:ncbi:9606">human</span>
Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes
###end article-title 126
###begin article-title 127
Distinct roles of CTLA-4 and TGF-beta in CD4(+)CD25(+) regulatory T cell function
###end article-title 127
###begin article-title 128
Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells
###end article-title 128
###begin article-title 129
###xml 101 107 <span type="species:ncbi:10090">murine</span>
Transforming growth factor-beta1-induced CD4+CD25+ regulatory T cells in vitro reverse and prevent a murine lupus-like syndrome of chronic graft-versus-host disease
###end article-title 129
###begin article-title 130
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Expression of intracellular transforming growth factor-beta1 in CD4(+)CD25(+) cells in patients with systemic lupus erythematosus
###end article-title 130

